Abbott Affirms Its Support for Mylan Standalone Strategy and Will Vote Its Mylan Shares in Favor of Mylan's Proposed Acquisition of Perrigo
Abbott today confirmed its continued support for Mylan N.V's growth strategy by stating its intent to vote its 14.5 percent stake in Mylan in favor of Mylan's proposed acquisition of Perrigo.
PRESS RELEASE
ABBOTT PARK, Ill.,
June 16, 2015
/
/ -- Abbott (NYSE: ABT) today confirmed its continued support for Mylan N.V's growth strategy by stating its intent to vote its 14.5 percent stake in Mylan in favor of Mylan's proposed acquisition of Perrigo.
"We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said
Miles D. White
, chairman and chief executive officer, Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."
